131 related articles for article (PubMed ID: 35086129)
1. Response to neoadjuvant chemotherapy and survival of children and adolescents with high-grade osteosarcoma treated based on the EURAMOS-1 protocol.
Suárez-Mattos A; Arroyave F; Infante AM; Narváez C; Soto C; Gómez L; Amaya-Nieto J
Bol Med Hosp Infant Mex; 2022; 79(1):17-25. PubMed ID: 35086129
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
Xu J; Xie L; Guo W
Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
[TBL] [Abstract][Full Text] [Related]
3. Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.
Erdoğan F; Çinka H; Akman BÇ; Coşkun HS; Dabak N
Jt Dis Relat Surg; 2023; 34(1):196-206. PubMed ID: 36700283
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
5. Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study.
Prabowo Y; Setiawan I; Kamal AF; Kodrat E; Labib Zufar ML
Int J Surg Oncol; 2021; 2021():8843325. PubMed ID: 33996154
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome.
Bacci G; Forni C; Ferrari S; Longhi A; Bertoni F; Mercuri M; Donati D; Capanna R; Bernini G; Briccoli A; Setola E; Versari M
J Pediatr Hematol Oncol; 2003 Nov; 25(11):845-53. PubMed ID: 14608193
[TBL] [Abstract][Full Text] [Related]
7. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
[TBL] [Abstract][Full Text] [Related]
8. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
[TBL] [Abstract][Full Text] [Related]
9. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
10. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
[TBL] [Abstract][Full Text] [Related]
11. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group.
Provisor AJ; Ettinger LJ; Nachman JB; Krailo MD; Makley JT; Yunis EJ; Huvos AG; Betcher DL; Baum ES; Kisker CT; Miser JS
J Clin Oncol; 1997 Jan; 15(1):76-84. PubMed ID: 8996127
[TBL] [Abstract][Full Text] [Related]
12. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
[TBL] [Abstract][Full Text] [Related]
13. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
15. P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA.
Tang Y; Yang C; Guo Z; Fu Y; Yu X; Liu B; Zhou H; Wang J; Li W; Pang Q
Medicine (Baltimore); 2017 May; 96(19):e6714. PubMed ID: 28489748
[TBL] [Abstract][Full Text] [Related]
16. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response.
Ferrari S; Mercuri M; Picci P; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Longhi A; Rimondini S; Donati D; Manfrini M; Ruggieri P; Biagini R; Bacci G
Tumori; 1999; 85(6):458-64. PubMed ID: 10774566
[TBL] [Abstract][Full Text] [Related]
17. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
[TBL] [Abstract][Full Text] [Related]
20. Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome.
Laux CJ; Berzaczy G; Weber M; Lang S; Dominkus M; Windhager R; Nöbauer-Huhmann IM; Funovics PT
Int Orthop; 2015 Jan; 39(1):97-104. PubMed ID: 25432323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
